{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:12:11Z","timestamp":1790716331033,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurologic.theclinics.com","mdconsult.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologic Clinics"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.ncl.2014.04.001","type":"journal-article","created":{"date-parts":[[2014,6,6]],"date-time":"2014-06-06T09:47:35Z","timestamp":1402048055000},"page":"629-646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":89,"title":["Inclusion Body Myositis"],"prefix":"10.1016","volume":"32","author":[{"given":"Mazen M.","family":"Dimachkie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Barohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ncl.2014.04.001_bib1","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/(SICI)1097-4598(200006)23:6<970::AID-MUS20>3.0.CO;2-I","article-title":"Prevalence of sporadic inclusion body myositis in Western Australia","volume":"23","author":"Phillips","year":"2000","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1016\/j.ncl.2014.04.001_bib2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1756-185X.2011.01669.x","article-title":"Incidence and prevalence of idiopathic inflammatory myopathies in South Australia: a 30-year epidemiologic study of histology-proven cases","volume":"16","author":"Tan","year":"2013","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.ncl.2014.04.001_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1600-0404.1994.tb01647.x","article-title":"Inclusion body myositis: clinical, morphological, physiological and laboratory findings in 18 cases","volume":"89","author":"Lindberg","year":"1994","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"10.1016\/j.ncl.2014.04.001_bib4","first-page":"445","article-title":"Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota","volume":"35","author":"Wilson","year":"2008","journal-title":"J\u00a0Rheumatol"},{"issue":"Pt 3","key":"10.1016\/j.ncl.2014.04.001_bib5","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/brain\/112.3.727","article-title":"Inclusion body myositis. Observations in 40 patients","volume":"112","author":"Lotz","year":"1989","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.ncl.2014.04.001_bib6","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s00415-005-0884-y","article-title":"Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients","volume":"252","author":"Badrising","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.04.001_bib7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ana.410400407","article-title":"Inclusion body myositis: clinical and pathological boundaries","volume":"40","author":"Amato","year":"1995","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2014.04.001_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11940-000-0019-9","article-title":"Inclusion body myositis","volume":"2","author":"Barohn","year":"2000","journal-title":"Curr Treat Options Neurol"},{"key":"10.1016\/j.ncl.2014.04.001_bib9","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1212\/WNL.55.9.1385","article-title":"Epidemiology of inclusion body myositis in the Netherlands: a nationwide study","volume":"55","author":"Badrising","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.04.001_bib10","first-page":"1385","article-title":"Inclusion body myositis: analysis of 32 cases","volume":"19","author":"Sayers","year":"1992","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.ncl.2014.04.001_bib11","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/jnnp.2007.138891","article-title":"Sporadic inclusion body myositis: phenotypic variability and influence of HLA-DR3 in a cohort of 57 Australian cases","volume":"79","author":"Needham","year":"2008","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.ncl.2014.04.001_bib12","first-page":"18","article-title":"Sporadic IBM: a case cohort","volume":"12","author":"Estephan","year":"2011","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"key":"10.1016\/j.ncl.2014.04.001_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.physio.2013.06.002","article-title":"Frequency and circumstances of falls in people with inclusion body myositis: a questionnaire survey to explore falls management and physiotherapy provision","volume":"100","author":"Hiscock","year":"2013","journal-title":"Physiotherapy"},{"issue":"2","key":"10.1016\/j.ncl.2014.04.001_bib14","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1097\/CND.0b013e3182650718","article-title":"Camptocormia due to inclusion body myositis","volume":"14","author":"Goodman","year":"2012","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"issue":"2","key":"10.1016\/j.ncl.2014.04.001_bib15","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4081\/ni.2013.e11","article-title":"Asymptomatic hyper-creatine-kinase-emia as sole manifestation of inclusion body myositis","volume":"5","author":"Finsterer","year":"2013","journal-title":"Neurol Int"},{"issue":"3","key":"10.1016\/j.ncl.2014.04.001_bib16","first-page":"155","article-title":"Primary respiratory failure due to inclusion body myositis: think outside the box","volume":"77","author":"Jethava","year":"2013","journal-title":"Conn Med"},{"issue":"7","key":"10.1016\/j.ncl.2014.04.001_bib17","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.45.7.1302","article-title":"Inclusion body myositis: explanation for poor response to immunosuppressive therapy","volume":"45","author":"Barohn","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.04.001_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/mus.24060","article-title":"Inclusion body myositis presenting with facial diplegia","volume":"49","author":"Ghosh","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2014.04.001_bib19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2249.1994.tb06604.x","article-title":"HLA associations with inclusion body myositis","volume":"98","author":"Garlepp","year":"1994","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.ncl.2014.04.001_bib20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/01.bor.0000434676.70268.66","article-title":"Entering a new phase of immunogenetics in the idiopathic inflammatory myopathies","volume":"25","author":"Rothwell","year":"2013","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"10.1016\/j.ncl.2014.04.001_bib21","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/jnnp.2009.173823","article-title":"Inclusion body myositis: old and new concepts","volume":"80","author":"Amato","year":"2009","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.ncl.2014.04.001_bib22","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jmri.20804","article-title":"Muscle MRI in inherited neuromuscular disorders: past, present, and future","volume":"25","author":"Mercuri","year":"2007","journal-title":"J\u00a0Magn Reson Imaging"},{"issue":"12","key":"10.1016\/j.ncl.2014.04.001_bib23","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1007\/s00256-010-0930-4","article-title":"Morphologic imaging in muscular dystrophies and inflammatory myopathies","volume":"39","author":"Degardin","year":"2010","journal-title":"Skeletal Radiol"},{"issue":"6","key":"10.1016\/j.ncl.2014.04.001_bib24","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/rheumatology\/ker001","article-title":"Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis","volume":"50","author":"Cox","year":"2011","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.ncl.2014.04.001_bib25","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1212\/WNL.44.8.1516","article-title":"Inclusion body myositis: treatment with intravenous immunoglobulin","volume":"44","author":"Amato","year":"1994","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.ncl.2014.04.001_bib26","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.21338","article-title":"A\u00a0phase I\/II trial of MYO-029 in adult subjects with muscular dystrophy","volume":"63","author":"Wagner","year":"2008","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2014.04.001_bib27","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/mrm.1910180211","article-title":"Three-point Dixon technique for true water\/fat decomposition with B0 inhomogeneity correction","volume":"18","author":"Glover","year":"1991","journal-title":"Magn Reson Med"},{"issue":"3","key":"10.1016\/j.ncl.2014.04.001_bib28","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/jmri.22849","article-title":"Quantitative assessment of skeletal muscle degeneration in patients with myotonic dystrophy type 1 using MRI","volume":"35","author":"Hiba","year":"2012","journal-title":"J\u00a0Magn Reson Imaging"},{"issue":"5","key":"10.1016\/j.ncl.2014.04.001_bib29","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1093\/rheumatology\/keh130","article-title":"Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis","volume":"43","author":"Maillard","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.ncl.2014.04.001_bib30","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1136\/jnnp.2009.197640","article-title":"Increased [11C]PIB-PET levels in inclusion body myositis are indicative of amyloid beta deposition","volume":"82","author":"Maetzler","year":"2011","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1016\/j.ncl.2014.04.001_bib31","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1212\/01.wnl.0000277527.69388.fe","article-title":"Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM","volume":"70","author":"Chahin","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.04.001_bib32","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0960-8966(00)00219-4","article-title":"Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis","volume":"11","author":"Van der Meulen","year":"2001","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.ncl.2014.04.001_bib33","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/mus.20649","article-title":"Myeloid dendritic cells in inclusion-body myositis and polymyositis","volume":"35","author":"Greenberg","year":"2007","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.ncl.2014.04.001_bib34","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.ncl.2014.04.001_bib35","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.nmd.2009.11.003","article-title":"Inclusion body myositis: MRC centre for neuromuscular diseases, IBM workshop, London, 13 June 2008","volume":"20","author":"Hilton-Jones","year":"2010","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.ncl.2014.04.001_bib36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/mus.21386","article-title":"Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis","volume":"40","author":"Salajegheh","year":"2009","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.ncl.2014.04.001_bib37","first-page":"103","article-title":"Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis","volume":"30","author":"Dubourg","year":"2011","journal-title":"Acta Myol"},{"issue":"6","key":"10.1016\/j.ncl.2014.04.001_bib38","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/BOR.0b013e32834b53cc","article-title":"Inclusion body myositis","volume":"23","author":"Greenberg","year":"2011","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.ncl.2014.04.001_bib39","doi-asserted-by":"crossref","first-page":"e20266","DOI":"10.1371\/journal.pone.0020266","article-title":"Autoantibodies against a 43 kDa muscle protein in inclusion body myositis","volume":"6","author":"Salajegheh","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.ncl.2014.04.001_bib40","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1212\/WNL.59.8.1170","article-title":"Molecular profiles of inflammatory myopathies","volume":"59","author":"Greenberg","year":"2002","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.ncl.2014.04.001_bib41","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1212\/01.wnl.0000187124.92826.20","article-title":"Plasma cells in muscle in inclusion body myositis and polymyositis","volume":"65","author":"Greenberg","year":"2005","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ncl.2014.04.001_bib42","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/ana.23840","article-title":"Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis","volume":"73","author":"Larman","year":"2013","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2014.04.001_bib43","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ana.23822","article-title":"Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis","volume":"73","author":"Pluk","year":"2013","journal-title":"Ann Neurol"},{"issue":"2 Suppl 1","key":"10.1016\/j.ncl.2014.04.001_bib44","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1212\/01.wnl.0000192128.13875.1e","article-title":"Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition","volume":"66","author":"Askanas","year":"2006","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ncl.2014.04.001_bib45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.nmd.2006.08.009","article-title":"Overexpression and proteasome inhibition increase alpha B-crystallin in cultured human muscle: relevance to inclusion-body myositis","volume":"16","author":"Wojcik","year":"2006","journal-title":"Neuromuscul Disord"},{"issue":"4 Pt 2","key":"10.1016\/j.ncl.2014.04.001_bib46","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.lpm.2010.11.024","article-title":"Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-\u03b242 oligomers and phosphorylated tau","volume":"40","author":"Askanas","year":"2011","journal-title":"Presse Med"},{"issue":"4","key":"10.1016\/j.ncl.2014.04.001_bib47","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/mus.21471","article-title":"Nature of \u201cTau\u201d immunoreactivity in normal myonuclei and inclusion body myositis","volume":"40","author":"Salajegheh","year":"2009","journal-title":"Muscle Nerve"},{"issue":"5","key":"10.1016\/j.ncl.2014.04.001_bib48","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00401-010-0737-3","article-title":"Novel demonstration of amyloid-\u03b2 oligomers in sporadic inclusion-body myositis muscle fibers","volume":"120","author":"Nogalska","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ncl.2014.04.001_bib49","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/00002281-200211000-00004","article-title":"Inclusion body myositis","volume":"14","author":"Tawil","year":"2002","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.ncl.2014.04.001_bib50","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/01.bor.0000434671.77891.9a","article-title":"Update in inclusion body myositis","volume":"25","author":"Machado","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.ncl.2014.04.001_bib51","first-page":"19","article-title":"Treatment-responsive polymyositis transforming into inclusion body myositis","volume":"P060","author":"Verma","year":"2008","journal-title":"Neurology"},{"issue":"Pt 11","key":"10.1016\/j.ncl.2014.04.001_bib52","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/brain\/awr213","article-title":"Long-term observational study of sporadic inclusion body myositis","volume":"134","author":"Benveniste","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.ncl.2014.04.001_bib53","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/WNL.48.3.712","article-title":"Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study","volume":"48","author":"Dalakas","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.04.001_bib54","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1212\/WNL.56.3.323","article-title":"A\u00a0controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM","volume":"56","author":"Dalakas","year":"2001","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.ncl.2014.04.001_bib55","doi-asserted-by":"crossref","first-page":"4094","DOI":"10.1002\/art.37692","article-title":"Provision of an explanation for the inefficacy of immunotherapy in sporadic inclusion body myositis: quantitative assessment of inflammation and \u03b2-amyloid in the muscle","volume":"64","author":"Zsch\u00fcntzsch","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ncl.2014.04.001_bib56","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1212\/WNL.57.9.1566","article-title":"Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis","volume":"57","author":"Muscle Study Group","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.04.001_bib57","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1212\/01.WNL.0000134675.98525.79","article-title":"Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis","volume":"63","author":"Muscle Study Group","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ncl.2014.04.001_bib58","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ana.10121","article-title":"Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo","volume":"51","author":"Badrising","year":"2002","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ncl.2014.04.001_bib59","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1212\/01.WNL.0000071852.27182.C7","article-title":"Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study","volume":"61","author":"Lindberg","year":"2003","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.ncl.2014.04.001_bib60","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1212\/WNL.58.7.1081","article-title":"A\u00a0pilot randomized trial of oxandrolone in inclusion body myositis","volume":"58","author":"Rutkove","year":"2002","journal-title":"Neurology"},{"issue":"2 Suppl 1","key":"10.1016\/j.ncl.2014.04.001_bib61","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1212\/01.wnl.0000192258.32408.54","article-title":"Pilot trial of etanercept in the treatment of inclusion-body myositis","volume":"66","author":"Barohn","year":"2006","journal-title":"Neurology"},{"issue":"Pt 6","key":"10.1016\/j.ncl.2014.04.001_bib62","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/brain\/awp104","article-title":"Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis","volume":"132","author":"Dalakas","year":"2009","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.ncl.2014.04.001_bib63","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10072-011-0657-6","article-title":"Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis","volume":"32","author":"Sancricca","year":"2011","journal-title":"Neurol Sci"},{"key":"10.1016\/j.ncl.2014.04.001_bib64","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jns.2013.08.007","article-title":"The effect of anakinra, an IL1 receptor antagonist, in patients with sporadic inclusion body myositis (sIBM): a small pilot study","volume":"334","author":"Kosmidis","year":"2013","journal-title":"J\u00a0Neurol Sci"},{"key":"10.1016\/j.ncl.2014.04.001_bib65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/CCRep.S10200","article-title":"Balloon dilation in sporadic inclusion body myositis patients with dysphagia","volume":"6","author":"Murata","year":"2013","journal-title":"Clin Med Insights Case Rep"},{"key":"10.1016\/j.ncl.2014.04.001_bib66","first-page":"2013","article-title":"Cricopharyngeal myotomy for cricopharyngeus stricture in an inclusion body myositis patient with hiatus hernia: a learning experience","volume":"22","author":"Sanei-Moghaddam","year":"2013","journal-title":"BMJ Case Rep"},{"issue":"4","key":"10.1016\/j.ncl.2014.04.001_bib67","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/mus.20958","article-title":"Inclusion body myositis functional rating scale: a reliable and valid measure of disease severity","volume":"37","author":"Jackson","year":"2008","journal-title":"Muscle Nerve"},{"issue":"Suppl 4","key":"10.1016\/j.ncl.2014.04.001_bib68","first-page":"A106","article-title":"Pilot trial of lithium treatment in inclusion body myositis","volume":"76","author":"Saperstein","year":"2011","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.ncl.2014.04.001_bib69","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/mus.21423","article-title":"Autophagy, lithium, and amyotrophic lateral sclerosis","volume":"40","author":"Pasquali","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ncl.2014.04.001_bib70","unstructured":"Wang Y, He J, McVey AL, et\u00a0al. Twelve-month change of IBMFRS in the arimocolomol inclusion body myositis pilot study. Poster 7.255 at the American Academy of Neurology Annual Meeting. New Orleans, April 26, 2012."},{"issue":"Suppl 17","key":"10.1016\/j.ncl.2014.04.001_bib71","first-page":"S95","article-title":"Twelve-month change of IBMFRS in the Arimocolomol Inclusion Body Myositis Pilot Study","volume":"74","author":"Wang","year":"2013","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.ncl.2014.04.001_bib72","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1055\/s-2008-1041132","article-title":"Inclusion body myositis: new concepts","volume":"13","author":"Sekul","year":"1993","journal-title":"Semin Neurol"},{"issue":"Pt 11","key":"10.1016\/j.ncl.2014.04.001_bib73","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1093\/brain\/awr217","article-title":"A\u00a012-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities","volume":"134","author":"Cox","year":"2011","journal-title":"Brain"},{"issue":"5","key":"10.1016\/j.ncl.2014.04.001_bib74","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.nmd.2013.02.010","article-title":"Longitudinal observational study of sporadic inclusion body myositis: implications for clinical trials","volume":"23","author":"Cortese","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.ncl.2014.04.001_bib75","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/16501970306110","article-title":"Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction","volume":"35","author":"Arnardottir","year":"2003","journal-title":"J\u00a0Rehabil Med"},{"key":"10.1016\/j.ncl.2014.04.001_bib76","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/CND.0b013e3181237291","article-title":"The effectiveness of an individualized, home-based functional exercise program for patients with sporadic inclusion body myositis","volume":"8","author":"Johnson","year":"2007","journal-title":"J\u00a0Clin Neuromuscul Dis"},{"issue":"4","key":"10.1016\/j.ncl.2014.04.001_bib77","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/CND.0b013e3181a23c86","article-title":"Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis","volume":"10","author":"Johnson","year":"2009","journal-title":"J\u00a0Clin Neuromuscul Dis"}],"container-title":["Neurologic Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861914000243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0733861914000243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T11:50:41Z","timestamp":1538567441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0733861914000243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0733861914000243"],"URL":"https:\/\/doi.org\/10.1016\/j.ncl.2014.04.001","relation":{},"ISSN":["0733-8619"],"issn-type":[{"value":"0733-8619","type":"print"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inclusion Body Myositis","name":"articletitle","label":"Article Title"},{"value":"Neurologic Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ncl.2014.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}